Keyphrases
Clinical Trials
100%
Placebo
100%
Attention Deficit Hyperactivity Disorder
100%
Placebo Response
100%
Lisdexamfetamine Dimesylate
100%
Randomized Double-blind
40%
Adult Subjects
40%
Group Studies
20%
Adverse Events
20%
Rating Scales
20%
Response Rate
20%
Demographic Factors
20%
Remission
20%
Pharmacotherapy
20%
Attention-deficit Hyperactivity Disorder Symptoms
20%
Comorbid
20%
Placebo-controlled
20%
Response Time
20%
Symptom Severity
20%
Remission Rate
20%
Trial Registration
20%
Medical Comorbidity
20%
Placebo Effect
20%
Psychiatric Comorbidity
20%
Time Response
20%
Temporal Profile
20%
Dose Titration
20%
Predictors of Remission
20%
Symptom Remission
20%
Factor Priors
20%
Clinical Global Impression
20%
Medical Symptoms
20%
Time to Remission
20%
DSM-IV-TR
20%
Baseline Severity
20%
Medicine and Dentistry
Clinical Trial
100%
Placebo
100%
Attention Deficit Disorder
100%
Lisdexamfetamine
100%
Placebo Effect
100%
Symptom
66%
Drug Therapy
33%
Adverse Event
16%
Rating Scale
16%
Spontaneous Remission
16%
Drug Dose Titration
16%
Clinical Global Impression
16%
DSM-IV-TR
16%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Placebo
100%
Attention Deficit Disorder
100%
Lisdexamfetamine
100%
Remission
45%
Symptom
36%
Adverse Event
9%
Pharmacotherapy
9%
Comorbidity
9%
DSM-IV-TR
9%
Neuroscience
Placebo
100%
Attention Deficit Hyperactivity Disorder
100%
Lisdexamfetamine
100%